Adial Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Adial Pharmaceuticals, Inc. (ADIL) had Deferred Tax Assets, Operating Loss Carryforwards of $14.99 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $14.99M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $13.96M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $12.30M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $11.10M; Deferred Tax Assets, Operating Loss Carryforwards as first filed $11.38M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $14.99M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $13.96M 10-K · filed 2026-03-05 | |
| 2023-12-31 | $12.30M 10-K · filed 2025-03-04 | |
| 2022-12-31 | $11.10M 10-K · filed 2024-04-01 | $11.38M 10-K · filed 2023-03-30 |
| 2021-12-31 | $9.67M 10-K · filed 2023-03-30 | |
| 2020-12-31 | $6.00M 10-K · filed 2022-03-28 | $23.29M 10-K · filed 2021-03-22 |
| 2019-12-31 | $14.12M 10-K · filed 2021-03-22 | |
| 2018-12-31 | $7.13M 10-K · filed 2020-03-20 | |
| 2017-12-31 | $404.00K 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |